Science Briefing

Key Highlights

Medicine · Diabetes & Endocrinology

A correspondence in The Lancet Diabetes & Endocrinology critically examines the 2025 WHO Essential Medicines List (EML) decision regarding GLP-1 receptor agonists, questioning their appropriateness for inclusion. The authors argue that weak diabetes care systems globally make adding such therapies unrealistic, that even in high-income countries these agents remain unaffordable despite potential cost-effectiveness, and that the WHO’s EML and guideline processes require greater alignment. For a leading diabetologist and National President of RSSDI, this analysis is directly relevant to ongoing debates about equitable access to advanced diabetes therapies and the practical challenges of translating global recommendations into clinical practice in India.

Novelty: 80%
   
Rigor: 85%
   
Significance: 75%
   
Validity: 90%
   
Clarity: 95%

Read the paper →

Update Your Briefing Preferences

Stay curious. Stay informed —

Science Briefing

Your briefing is personalized based on your selected fields, keywords, and research interests.